2,328 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Main Management ETF Advisors LLC

Main Management ETF Advisors LLC acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 2,328 shares of the biotechnology company's stock, valued at approximately $834,000.

Several other large investors also recently modified their holdings of the stock. ClariVest Asset Management LLC boosted its holdings in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock worth $25,000 after acquiring an additional 42 shares in the last quarter. V Square Quantitative Management LLC acquired a new position in shares of United Therapeutics in the 2nd quarter worth approximately $30,000. Innealta Capital LLC acquired a new position in shares of United Therapeutics in the 2nd quarter worth approximately $33,000. USA Financial Formulas acquired a new position in shares of United Therapeutics in the 3rd quarter worth approximately $33,000. Finally, Brooklyn Investment Group acquired a new position in shares of United Therapeutics in the 3rd quarter worth approximately $33,000. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CFO James Edgemond sold 7,802 shares of United Therapeutics stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the sale, the chief financial officer now owns 3,210 shares of the company's stock, valued at approximately $1,108,766.10. The trade was a 70.85 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Judy D. Olian sold 1,750 shares of United Therapeutics stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $412.48, for a total transaction of $721,840.00. Following the sale, the director now directly owns 5,655 shares in the company, valued at $2,332,574.40. The trade was a 23.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 127,142 shares of company stock worth $47,460,419 in the last 90 days. 11.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on UTHR shares. Jefferies Financial Group upped their price objective on United Therapeutics from $315.00 to $432.00 and gave the stock a "buy" rating in a report on Monday, September 23rd. TD Cowen upped their price objective on United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Oppenheimer upped their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. Wells Fargo & Company increased their price target on United Therapeutics from $350.00 to $380.00 and gave the company an "overweight" rating in a research note on Tuesday, August 20th. Finally, HC Wainwright increased their price target on United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $370.86.

United Therapeutics Stock Performance

NASDAQ:UTHR traded down $4.70 on Friday, hitting $369.67. The stock had a trading volume of 199,272 shares, compared to its average volume of 303,476. The stock has a market cap of $16.51 billion, a P/E ratio of 16.23, a price-to-earnings-growth ratio of 1.07 and a beta of 0.54. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $417.82. The firm's fifty day simple moving average is $369.14 and its two-hundred day simple moving average is $339.06.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics's revenue for the quarter was up 22.9% on a year-over-year basis. During the same period last year, the firm earned $5.38 EPS. Equities research analysts predict that United Therapeutics Co. will post 25.22 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.